News Novo Nordisk cuts GLP-1 prices for cash buyers Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.
News Novo Nordisk claims first GLP-1 approval in MASH Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.
News Novo Nordisk weakens again on interim results readout Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.
News Noom expands its GLP-1 range with 'microdose' package Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.
News Novo Nordisk slumps as it cuts sales forecast, names new CEO Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.
News Novo Nordisk files high-dose Wegovy in EU Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
